Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
A Delphi consensus of 23 experts identified Zostavax, sildenafil and riluzole as high-priority candidates for Alzheimer disease clinical trials. Caregivers ranked the herpes zoster vaccine highest for acceptability and perceived benefit–risk balance.
Deep learning studies using MRI, genetics and longitudinal imaging reported improved dementia risk prediction and mapped dynamic brain-region changes during Alzheimer’s disease progression.
Recent research identifies novel genetic causes for rare movement and neurodegenerative disorders, including CD99L2 variants in spastic ataxia, PPP2R5C as an Alzheimer's biomarker, and toxic polyglycine proteins in GGC repeat expansion diseases.
New research identifies a key microglial subpopulation regulated by anti-TREM2 antibody therapy in Alzheimer's disease, revealing how the treatment guides microglia toward protective differentiation pathways.
Research initiatives are identifying novel therapeutic targets for Alzheimer's disease beyond traditional approaches, with focus on TREM2 agonists, metabolic interventions, and multi-omic data integration to diversify treatment strategies.
Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.
Researchers at Washington University in St. Louis have adapted CAR-T immunotherapy to target aggregated amyloid-beta in mice, with transient CAR expression clearing brain plaques. The approach uses CD4+ T cells engineered with receptors based on lecanemab antibody sequences.
Blood-based biomarkers including brain-derived tau and amyloid-beta are enabling earlier Alzheimer's disease diagnosis through non-invasive testing, though confirmatory imaging remains necessary before treatment initiation.
Longeveron Inc. appointed Stephen H. Willard as CEO effective February 11, 2026, replacing interim CEO Than Powell. The appointment comes as the company expects top-line results from its pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome in Q3 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07252440 |
A Study to Evaluate the Efficacy and Safety of TTYP01 Tablets in Early Symptomatic Alzheimer's Disease |
RECRUITING | PHASE2 |
| NCT07100470 |
Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET |
NOT_YET_RECRUITING | NA |
| NCT07011706 |
ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06593626 |
A Phase I Clinical Study on the Safety and Pharmacokinetics of [18F]Florbetazine Injection |
COMPLETED | PHASE1 |
| NCT06335836 |
The Effects of Social Isolation and Social Interaction on the Risk of Dementia Progression and Brain Function in SCD (Subjective Cognitive Decline, SCD) |
RECRUITING | |
| NCT06245031 |
Extension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015) |
ENROLLING_BY_INVITATION | NA |
| NCT06155201 |
Development and Application of Intelligent Diagnosis and Treatment Norms for Children and Adolescents With Mental Disorders |
RECRUITING | NA |
| NCT05984784 |
A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) |
TERMINATED | PHASE1/PHASE2 |
| NCT05372458 |
The Mechanism Study of Diabetic Pancreatic Amyloid Deposition on Cognitive Dysfunction in Alzheimer's Disease |
UNKNOWN | |
| NCT04520308 |
An Open-label, Single-arm Longitudinal Study With Dupilumab for Patients With Atopic Dermatitis |
UNKNOWN | PHASE4 |
